by Madaline Spencer and Joe Haddad | Oct 14, 2025
May Lee Tjoa, PhD, Senior Global Medical Affairs Leader: Nipocalimab and Maternal-Fetal Immunology at Johnson & Johnson, discusses data on hemolytic disease of the fetus and newborn (HDFN) from the 2025 ISUOG World Congress on Ultrasound in Obstetrics and...
by Madaline Spencer and Scott Harwood | Oct 13, 2025
Amit Mehta, MD, Medical Oncologist, discusses data that led to the approval of Wayrilz (rilzabrutinib) for adult patients with immune thrombocytopenia (ITP). ITP is a bleeding disorder characterized by low levels of platelets. It is an autoimmune disorder in...
by Madaline Spencer | Oct 10, 2025
Mike Flanagan, PhD, Chief Scientific Officer at Avidity Biosciences, discusses new data from the EXPLORE44 open-label extension of del-zota for treatment of patients with Duchenne muscular dystrophy (DMD) amenable to exon 44 skipping. DMD affects the...
by Madaline Spencer | Oct 9, 2025
The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast) tablets for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is the first new therapy to be approved in this indication for 10 years. IPF is a rare, progressive...
by Madaline Spencer and Joe Haddad | Oct 9, 2025
Jannine Williams, Compound Development Team Leader at Johnson & Johnson, discusses key takeaways from studies on hemolytic disease of the fetus and newborn (HDFN) presented at ISUOG World Congress 2025. HDFN is a rare condition characterized by the...
